GlassScriptPhysician profile
Kiley K Walp
NPI 1497981237
$7,722.23
in general payments reported to CMS, 2019-2025
37 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,569 · 2020: $548 · 2021: $952 · 2022: $1,233 · 2023: $1,422 · 2024: $1,606 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.08 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,125.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $660.11 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $509.15 | 2019-2024 | Stelara, Simponi Aria, Remicade |
| Pfizer INC. | $401.57 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $401.26 | 2019-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $388.99 | 2019-2024 | Livdelzi |
| Braintree Laboratories, INC. | $327.78 | 2019-2024 | Suflave, Sutab |
| Celgene Corporation | $307.63 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $226.92 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $217.39 | 2019-2024 | Dificid, Zinplava, Zerbaxa |
| Medtronic, INC. | $190.63 | 2024-2025 | Interstim |
| Ferring Pharmaceuticals INC. | $186.05 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $179.02 | 2019-2025 | Linzess |
| Shionogi INC | $167.51 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $159.12 | 2023 | Zeposia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $145.59 | 2023-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $144.36 | 2019-2024 | Ocaliva |
| Ardelyx, INC. | $137.17 | 2023-2025 | Ibsrela |
| Thd America, INC. | $124.23 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $123.59 | 2023-2025 | Dupixent |
| Genzyme Corporation | $100.96 | 2022-2024 | |
| Daiichi Sankyo INC. | $68.65 | 2019-2024 | Injectafer |
| Celltrion USA INC. | $67.52 | 2024-2025 | Vegzelma, Zymfentra |
| Ucb, INC. | $63.53 | 2019 | |
| Nestle Healthcare Nutrition INC. | $45.88 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $45.24 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $39.28 | 2023-2024 | Idacio |
| Sandoz INC. | $32.96 | 2024 | Hyrimoz |
| Madrigal Pharmaceuticals | $25.08 | 2024 | Resmetirom |
| Amag Pharmaceuticals, INC. | $18.95 | 2021 | |
| Concordia Pharmaceuticals INC. | $16.60 | 2019 | |
| Qol Medical, LLC | $16.17 | 2023 | Sucraid |
| Redhill Biopharma INC. | $16.14 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.75 | 2024 | Voquezna |
| Intra-Sana Laboratories | $14.32 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Allergan, INC. | $11.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiley Walp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.